Impax Settles IP Row With J&J Over Generic Concerta

Law360, New York (September 14, 2012, 7:23 PM EDT) -- Impax Laboratories Inc. on Friday inked a deal with two Johnson & Johnson subsidiaries, giving Impax licensing rights to produce generic versions of the attention deficit hyperactivity disorder drug Concerta and putting to rest a lengthy patent infringement battle against the generic drugmaker.

Under the agreement reached with Alza Corp. and Janssen Pharmaceuticals Inc., Impax may sell generic Concerta tablets in 18-, 27-, 36- and 54-milligram dosages effective July 14. Impax's settlement also authorizes Teva Pharmaceuticals USA Inc. to market Impax’s generic Concerta tablets.

Janssen owns...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.